Revance Therapeutics (RVNC) Reports Q2 Loss of $0.86/Share

August 5, 2019 4:35 PM

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.86), versus ($0.94) reported last year. Revenue for the quarter came in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found